Loading clinical trials...

COMPLETED

Validation of a Sensor for Non-Invasive Measurements

Validation of a Sensor for Non-Invasive Measurement of Vital Signs, Hemodynamic Parameters and Time-Dependent Physiological Waveforms

NCT03463148•Baxter Healthcare Corporation

View on ClinicalTrials.gov

Summary

Subjects will be measured with both a sensor and a reference device

Detailed Description

Subjects will participate in a study measuring a single set of paired values. In this case, measurements will take roughly 2-30 minutes to complete, and will involve: 1) attaching the sensor on the subject; 2) attaching one or more reference devices to the subject; 3) making measurements with both the sensor and reference device, either simultaneously or sequentially; and 4) collecting and analyzing the paired value.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Subject is at least 18 (eighteen) years of age at screening.
•2. Subject and/or legally authorized person/representative is willing to undergo the Informed Consent process prior to enrollment in the study.
•3. Subject selection will not be based on age, height, or weight.
•4. Subject is a candidate for this study based on the PI's opinion and knowledge of the subject's condition as well as the features of the investigational device tested during the study.

Exclusion Criteria

•1. Subject is participating in another clinical study that may affect the results of either study.
•2. Subjects that are pregnant will not be included in the study.
•3. Subject is unable or not willing to wear electrode patches as required for a period of up to 168 hours.
•4. Subject is considered by the Principal Investigator to be medically unsuitable for study participation.

Locations (1)

toSense, Inc. Headquarters

San Diego, California, United States

Key Dates

Start Date

October 24, 2017

Primary Completion Date

April 19, 2021

Completion Date

April 19, 2021

Last Updated

January 20, 2022

Enrollment

136

ACTUAL participants

Conditions

CHFRenal DiseaseHypertension

Natural History of Noncirrhotic Portal Hypertension

NCT02417740

Cystic FibrosisImmunologic Deficiency Syndrome+3 more

View study

RECRUITINGNA

Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

NCT04634916

Kidney Disease, End-StageEnd-stage Renal Disease+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 20, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Validation of a Sensor for Non-Invasive Measurements

Inclusion Criteria

Exclusion Criteria

Natural History of Noncirrhotic Portal Hypertension

Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication

Penn Medicine Healthy Heart